Translational Functional Cancer Genomics

Research Group Translational Functional Cancer Genomics

Prof. Dr. Hanno Glimm / Dr. Friederike Herbst

Our aim is to understand the implications of inter- and intratumoral heterogeneity and to identify novel strategies for personalized treatment approaches.
© dkfz.de

Profound patient specific differences in cancer-causing aberrations as well as functional heterogeneity within individual tumors pose major challenges for the development of mechanism-based strategies in clinical cancer care. To understand the implications of inter- and intratumoral heterogeneity for personalized treatment approaches scientists and physicians from the Translational Functional Cancer Genomics group study the genomic and functional properties of tumor-cell subpopulations. They use their insights gained from multi-dimensional analysis of individual tumor samples and functional testing of patientderived tumor models to identify and approve novel treatment strategies.

Specific cultures are generated from individual tumor samples of patients that receive comprehensive molecular profiling in the MASTER (Molecularly Aided Stratification for Tumor Eradication) program, to functionally characterize their properties. Using our strong background and expertise in the field of stem cell and molecular cancer biology, we investigate the clonality, heterogeneity and functional characteristics of patient specific primary tumors and their respective model systems, also addressing subpopulation dynamics in benign and malignant stem cell fractions. As tumor-initiating cells very often hijack regulatory mechanisms, which are strictly controlled in benign stem cell systems, we specifically implement high-throughput screening approaches together with state-of-the-art single cell analyses and mouse genetics to delineate critical and deregulated factors leading to tumor initiation, metastasis formation and therapy resistance. Identified mechanistic insights are translated into clinical treatment strategies whenever possible.

The group of Translational Functional Cancer Genomics in Heidelberg joins forces with researchers of the Department of Translational Medical Oncology in Dresden to combine complementary strengths of both NCT partner sides in shared translational research programs.

Contact

Prof. Dr. Hanno Glimm / Dr. Friederike Herbst
Translational Functional Cancer Genomics (B280)
Deutsches Krebsforschungszentrum
und Nationales Centrum für Tumorerkrankungen (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg
Tel: +49 351 458-5540


Dr. Friederike Herbst
Tel: +49 6221 56-37146
E-Mail: friederike.herbst (at) nct-heidelberg.de

Selected Publications

  • Wünsche P*, Eckert ESP*, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F§, Glimm H§. (2018). Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs. Cell Stem Cell, 23, 132-146
  • Heining C*, Horak P*, Uhrig S*, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S§, Glimm H§. (2018). NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov., 8, 1087-1095
  • Giessler KM*, Kleinheinz K*, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H. (2017). Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med., 214, 2073-2088
  • Weischenfeldt J*, Dubash T*, Drainas AP*, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H§, Korbel JO§. (2017). Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet., 49, 65-74
to top